Cancer immunotherapies, developed to overcome the immune escape mechanisms of cancer progression and metastatic dissemination, are becoming familiar to oncologists (1), especially for programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors. Here, CD274 is linked to cancer.